Results Published From Two Phase III Trials of Oral Ozanimod in People With Relapsing National Multiple Sclerosis Society
September 05, 2019
September 05, 2019
NEW YORK, Sept. 5 -- The National Multiple Sclerosis Society issued the following news:
* * *
- Results of two phase III trials of oral ozanimod (Celgene Corporation) have been published. In both studies, ozanimod significantly reduced the relapse rate compared with Avonex(R) (interferon beta-1a, Biogen), and also reduced MRI-detected disease activity and brain atrophy. Ozanimod appeared to be well-tolerated during the studies.
- Both phase III studies were . . .
* * *
- Results of two phase III trials of oral ozanimod (Celgene Corporation) have been published. In both studies, ozanimod significantly reduced the relapse rate compared with Avonex(R) (interferon beta-1a, Biogen), and also reduced MRI-detected disease activity and brain atrophy. Ozanimod appeared to be well-tolerated during the studies.
- Both phase III studies were . . .